NASDAQ:PRPO - Precipio Stock Price, Price Target & More

$0.43 0.00 (0.00 %)

(As of 04/25/2018 01:04 AM ET)

Previous Close$0.43

Today's Range$0.42 - $0.44

52-Week Range$0.37 - $28.16

Volume162,653 shs

Average Volume1.01 million shs

Market Capitalization$8.71 million

P/E RatioN/A

Dividend YieldN/A

Beta0.56

About Precipio (NASDAQ:PRPO)

Precipio, Inc. provides platform to eradicate the problem of misdiagnosis within academic institutions. The company also delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:PRPO

CUSIPN/A

Webwww.precipiodx.com

Phone203-787-7888

Debt

Debt-to-Equity Ratio0.23%

Current Ratio0.17%

Quick Ratio0.16%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.72 million

Price / Sales4.92

Cash FlowN/A

Price / CashN/A

Book Value$1.28 per share

Price / Book0.34

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-20,690,000.00

Net Margins-1,374.79%

Return on Equity-289.33%

Return on Assets-93.68%

Miscellaneous

Employees33

Outstanding Shares19,690,000

How to Become a New Pot Stock Millionaire

Precipio (NASDAQ:PRPO) Frequently Asked Questions

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

When did Precipio's stock split? How did Precipio's stock split work?

Precipio shares reverse split on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

How were Precipio's earnings last quarter?

Precipio (NASDAQ:PRPO) issued its quarterly earnings data on Friday, August, 12th. The biotechnology company reported ($3.00) EPS for the quarter. The biotechnology company earned $0.51 million during the quarter. Precipio had a negative net margin of 1,374.79% and a negative return on equity of 289.33%. View Precipio's Earnings History.

Who are some of Precipio's key competitors?

Some companies that are related to Precipio include Aethlon Medical (AEMD), Arrayit (ARYC), Pressure BioSciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Who are Precipio's key executives?

Precipio's management team includes the folowing people:

Mr. Ilan Danieli, Founder, CEO & Pres
Mr. Carl R. Iberger, CFO & Sec.
Zaki Sabet, VP of Operations
Mr. Douglas Sites, VP of Sales
Mr. Stephen R. Miller, Chief Commercial Officer (Age 52)

Has Precipio been receiving favorable news coverage?

News articles about PRPO stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Precipio earned a coverage optimism score of 0.21 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 43.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $0.43.

How big of a company is Precipio?

Precipio has a market capitalization of $8.71 million and generates $1.72 million in revenue each year. Precipio employs 33 workers across the globe.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]

MarketBeat Community Rating for Precipio (PRPO)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		68 (Vote Outperform)
Underperform Votes:		66 (Vote Underperform)
Total Votes:		134

MarketBeat's community ratings are surveys of what our community members think about Precipio and other stocks. Vote "Outperform" if you believe PRPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Precipio (NASDAQ:PRPO) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 4/25/2016 forward)

Precipio (NASDAQ:PRPO) Earnings History and Estimates Chart

Earnings by Quarter for Precipio (NASDAQ:PRPO)

Precipio (NASDAQ PRPO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/20/2017	Q3 2017		($1.22)		$0.33 million	View	N/A
8/21/2017	Q2 2017		($15.35)		$0.26 million	View	N/A
5/18/2017	Q1 2017		($2.10)		$0.66 million	View	N/A
11/14/2016	Q3 2016		($2.40)		$0.46 million	View	N/A
8/12/2016	Q216		($3.00)		$0.51 million	View	Listen
5/23/2016	Q116		($3.00)		$0.24 million	View	Listen
11/12/2015	Q315	($8.10)	($5.40)	$6.65 million	$4.00 million	View	Listen
8/13/2015	Q215	($12.30)	($9.00)	$7.10 million	$7.00 million	View	Listen
5/14/2015	Q115	($15.60)	($10.80)	$6.80 million	$6.51 million	View	Listen
4/15/2015	Q414	($16.80)	($23.10)	$6.20 million	$7.70 million	View	N/A
10/30/2014		($17.40)	($18.30)	$6.80 million	$6.37 million	View	N/A
8/6/2014	Q2 2014	($15.92)	($17.12)	$6.25 million	$6.76 million	View	N/A
5/7/2014		($14.10)	($18.00)	$6.73 million	$6.25 million	View	N/A
3/12/2014		($10.80)	($1.50)	$6.71 million	$6.22 million	View	N/A
11/6/2013	Q3 2013	($10.82)	($21.63)		$6.65 million	View	N/A
8/6/2013	2Q13	($0.90)	($0.90)	$7.96 million	$7.31 million	View	N/A
5/8/2013	1Q13	($0.90)	($1.20)	$7.53 million	$7.37 million	View	N/A
3/13/2013	4Q12	($0.90)	($0.90)			View	N/A
11/7/2012	Q3 2012	($10.82)	($14.42)			View	N/A
8/1/2012	Q2 2012	($3.61)	($3.61)			View	N/A
5/8/2012	Q1 2012	($7.21)	($16.58)			View	N/A
3/7/2012	Q4 2011	($7.21)	$0.36			View	N/A
11/9/2011	Q3 2011		($11.18)			View	N/A
8/11/2011	Q2 2011	($10.82)	($8.29)			View	N/A
5/12/2011	Q1 2011		($5.05)			View	N/A
3/10/2011	Q4 2010		($5.77)			View	N/A
11/15/2010	Q3 2010		($6.49)			View	N/A
8/12/2010	Q2 2010		($8.29)			View	N/A
5/5/2010	Q1 2010		($2.52)			View	N/A
2/24/2010	Q4 2009		$1.08			View	N/A
11/5/2009	Q3 2009		($2.52)			View	N/A
8/12/2009	Q2 2009		($5.41)			View	N/A
5/13/2009	Q1 2009		($6.85)			View	N/A
3/18/2009	Q4 2008		($1.44)			View	N/A
10/29/2008	Q3 2008		($3.61)			View	N/A
5/7/2008	Q1 2008		$0.72			View	N/A
2/28/2008	Q4 2007		$2.52			View	N/A

(Earnings results data provided by Zacks Investment Research)

Precipio (NASDAQ:PRPO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Precipio (NASDAQ PRPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 11.40%

Insider Trading History for Precipio (NASDAQ:PRPO)

Precipio (NASDAQ PRPO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/22/2014	Leroy C Kopp	Major Shareholder	Sell	413,050	$3.70	$1,528,285.00
10/2/2013	Leroy C Kopp	Major Shareholder	Buy	9,000	$0.39	$3,510.00

(Data available from 1/1/2013 forward)

Precipio (NASDAQ PRPO) News Headlines

Source:

Date	Headline
	Precipio Completes a $3M Convertible Debt Facility finance.yahoo.com - April 23 at 9:23 AM
	Precipio (PRPO) Says It's in Strategic Partnership Discussions for IV-Cell www.streetinsider.com - April 19 at 9:43 AM
	Precipio Launches ICE COLD-PCR™ Research Access Program for Cancer Centers finance.yahoo.com - April 11 at 10:22 AM
	Precipio Inc (NASDAQ:PRPO): Time For A Financial Health Check finance.yahoo.com - April 10 at 4:17 PM
	Technical Perspectives on Medical Research Stocks -- Organovo, PerkinElmer, Precipio, and Thermo Fisher Scientific www.bizjournals.com - April 10 at 10:07 AM
	Harvard Bioscience (HBIO) versus Precipio (PRPO) Financial Review www.americanbankingnews.com - April 8 at 11:23 AM
	Head to Head Review: Coherent (COHR) & Precipio (PRPO) www.americanbankingnews.com - April 8 at 7:20 AM
	Precipio (PRPO) Says JAMA Article Underscores Superiority of its Liquid Biopsy Core Technology www.streetinsider.com - April 3 at 10:01 AM
	Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology finance.yahoo.com - April 3 at 10:01 AM
	Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection finance.yahoo.com - March 28 at 9:56 AM
	Precipio enters India liquid biopsy market with adoption by leading laboratory; shares ahead 25% premarket seekingalpha.com - March 26 at 10:10 AM
	Precipio Enters India Liquid Biopsy Market with Adoption by Leading Laboratory finance.yahoo.com - March 26 at 10:10 AM
	Precipio Restructures Capitalization Table finance.yahoo.com - March 22 at 9:56 AM
	Precipio (PRPO) Halted on Second LUDP Following Earlier PR www.streetinsider.com - March 21 at 10:54 AM
	Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform finance.yahoo.com - March 20 at 9:54 AM
	Precipio Settles Lawsuit with Crede Capital finance.yahoo.com - March 13 at 10:03 AM
	Key Measure of Precipio’s Pathology Sales Growth 4X Prior Quarter finance.yahoo.com - February 22 at 9:28 AM
	Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance finance.yahoo.com - February 15 at 8:54 AM
	Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter finance.yahoo.com - February 9 at 9:04 AM
	Precipio Enters Japanese Liquid Biopsy Market with First Hospital Sale finance.yahoo.com - February 6 at 8:59 AM
	Precipio (PRPO) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - February 4 at 5:02 PM
	Analyzing Precipio (PRPO) and Sunesis Pharmaceuticals (SNSS) www.americanbankingnews.com - January 28 at 11:12 PM
	Reviewing Brainstorm Cell Therapeutics (BCLI) & Precipio (PRPO) www.americanbankingnews.com - January 24 at 9:28 PM
	Critical Comparison: Precipio (PRPO) versus Its Peers www.americanbankingnews.com - January 23 at 5:30 PM
	Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania finance.yahoo.com - January 22 at 5:40 PM
	Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy finance.yahoo.com - January 10 at 9:04 AM
	Financial Comparison: Precipio (PRPO) vs. Its Competitors www.americanbankingnews.com - December 28 at 11:40 AM
	Precipio (PRPO) versus Its Competitors Head-To-Head Contrast www.americanbankingnews.com - December 28 at 5:50 AM
	Precipio Launches Its Second New ICE-COLD PCR™ Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies On Sanger Sequencing Platforms finance.yahoo.com - December 20 at 8:58 AM
	Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media - GlobeNewswire (press release) globenewswire.com - December 16 at 8:59 AM
	Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media finance.yahoo.com - December 14 at 9:03 AM
	Transgenomic (PRPO) Lifted to Sell at ValuEngine www.americanbankingnews.com - December 2 at 8:28 PM
	Precipio, Inc. :PRPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017 finance.yahoo.com - December 1 at 4:21 PM
	Precipio, Inc. to Host Earnings Call finance.yahoo.com - November 21 at 9:31 AM
	Precipio To Announce Third Quarter 2017 Financial Results and Provide a Company Update on Monday, November 20, 2017 at 4:05pm Eastern Time finance.yahoo.com - November 18 at 11:03 AM
	Precipio, Inc. Announces Pricing Of $2,748,000 Registered Direct Offering finance.yahoo.com - November 4 at 9:05 AM
	Reviewing Transgenomic (PRPO) and Voyager Therapeutics (VYGR) www.americanbankingnews.com - November 4 at 1:20 AM
	Precipio's ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy Platform finance.yahoo.com - November 2 at 7:56 AM
	Precipio's ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy Platform finance.yahoo.com - November 2 at 7:56 AM
	Precipio Announces Completion of Substantial Balance Sheet Restructuring finance.yahoo.com - November 2 at 7:56 AM
	Precipio Announces Completion of Substantial Balance Sheet Restructuring finance.yahoo.com - November 2 at 7:56 AM
	Precipio Receives First Ice Cold- Pcr(TM) Kit Order From Clearbridge Health finance.yahoo.com - October 31 at 8:08 AM
	Precipio Inc.: Precipio Delivers First ICE COLD-PCR Order To New Brazilian Distributor www.finanznachrichten.de - October 27 at 11:32 AM
	Precipio Delivers First ICE COLD-PCR(TM) Order To New Brazilian Distributor finance.yahoo.com - October 27 at 11:32 AM
	Precipio's ICE COLD-PCR(TM) Technology Selected by the University of Kentucky for Liquid Biopsy Study finance.yahoo.com - October 17 at 4:14 PM
	Precipio Launches Its First Re-Designed ICE-COLD PCR(TM) Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies finance.yahoo.com - October 12 at 8:31 AM
	Reviewing Transgenomic (PRPO) & Asterias Biotherapeutics (AST) www.americanbankingnews.com - October 11 at 8:48 AM
	Precipio Re-Launches All CLIA Lab and Pharmacological Research Projects at its New Haven, CT Facility finance.yahoo.com - October 11 at 6:46 AM
	Precipio Elects Jeffrey Cossman, MD, and Douglas Fisher, MD to its Board of Directors finance.yahoo.com - October 3 at 11:05 AM
	Contrasting FibroGen (FGEN) and Transgenomic (PRPO) www.americanbankingnews.com - September 30 at 4:32 AM

Precipio (NASDAQ:PRPO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Precipio (NASDAQ:PRPO) Income Statement, Balance Sheet and Cash Flow Statement

Precipio (NASDAQ PRPO) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff